Candriam S.C.A. Acquires New Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC)

Candriam S.C.A. acquired a new stake in Revance Therapeutics, Inc. (NASDAQ:RVNC) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 299,039 shares of the biopharmaceutical company’s stock, valued at approximately $909,000. Candriam S.C.A. owned about 0.29% of Revance Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. LMR Partners LLP bought a new position in Revance Therapeutics in the 3rd quarter valued at approximately $11,648,000. Alpine Associates Management Inc. acquired a new position in Revance Therapeutics in the 3rd quarter valued at approximately $21,605,000. Oddo BHF Asset Management Sas acquired a new position in Revance Therapeutics in the 3rd quarter valued at approximately $3,763,000. FNY Investment Advisers LLC increased its position in Revance Therapeutics by 160.4% in the 4th quarter. FNY Investment Advisers LLC now owns 477,823 shares of the biopharmaceutical company’s stock valued at $1,452,000 after acquiring an additional 294,323 shares during the period. Finally, Wellington Management Group LLP acquired a new position in Revance Therapeutics in the 3rd quarter valued at approximately $2,315,000. Institutional investors own 97.70% of the company’s stock.

Revance Therapeutics Stock Performance

NASDAQ:RVNC opened at $3.65 on Tuesday. The stock has a market capitalization of $381.02 million, a price-to-earnings ratio of -1.89 and a beta of 0.90. The firm has a fifty day simple moving average of $3.55 and a two-hundred day simple moving average of $4.41. Revance Therapeutics, Inc. has a 12 month low of $2.30 and a 12 month high of $7.56.

Analyst Ratings Changes

Several equities analysts have issued reports on RVNC shares. Mizuho decreased their price target on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a research report on Tuesday, December 10th. StockNews.com began coverage on shares of Revance Therapeutics in a research report on Monday. They issued a “hold” rating for the company. Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a research report on Friday, January 17th. Finally, Barclays decreased their price objective on shares of Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a research report on Monday, December 23rd. Nine analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, Revance Therapeutics presently has a consensus rating of “Hold” and an average price target of $8.39.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.